Small Cell Lung Carcinoma
Conditions
Brief summary
There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF
Detailed description
The main objective of this study is to determine whether patients with SCLC who have a metabolically active residual tumor in the fluorodeoxyglucose (FDG) PET/CT scan after two to three cycles of induction chemotherapy have a similarly low local recurrence rate with higher dose. There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF. Allocation to PET boost, if confirmed vital tumor rest by PET CT and biopsy.
Interventions
RADIATIONPET based Raditherapy boost
An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.
Sponsors
University Hospital, Essen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histopathologic confirmation * Limited disease
Exclusion criteria
* Other histology than small cell lung cancer * Further tumor diagnosis * ECOG 3 or worse * Extensive disease * stage IV
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local recurrence free survival | 2 months to 5 years | Local recurrence free survival |
| Distant recurrence free survival | 2 months to 5 years | Distant recurrence free survival |
| Overall survival | 2 months to 5 years | Overall survival |
Countries
Germany
Contacts
Primary ContactMaja Guberina
Outcome results
None listed